Androgen deprivation therapy in men with prostate cancer: How should the side effects be monitored and treated?

Clinical Endocrinology

Volumn 74, Issue 3, 2011, Pages 289-293

  Grossmann, Mathis ^a   Zajac, Jeffrey D ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CYPROTERONE ACETATE; DENOSUMAB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; PHOSPHODIESTERASE V INHIBITOR; PROSTATE SPECIFIC ANTIGEN; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE; TOREMIFENE; TRIACYLGLYCEROL; VENLAFAXINE; VITAMIN D;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; BLOOD PRESSURE MONITORING; BODY COMPOSITION; BODY FAT; BODY MASS; BONE DENSITY; CALCIUM INTAKE; CANCER FATIGUE; CANCER LOCALIZATION; CANCER PATIENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; EXERCISE; FRACTURE; GYNECOMASTIA; HAIR LOSS; HIP FRACTURE; HOT FLUSH; HUMAN; INSULIN RESISTANCE; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MALE; MALE SEXUAL DYSFUNCTION; MONOTHERAPY; MOOD; MUSCLE ATROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOPENIA; PATIENT COUNSELING; PATIENT MONITORING; PENIS PROSTHESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SPINE FRACTURE; TESTOSTERONE BLOOD LEVEL; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN INTAKE; WAIST CIRCUMFERENCE;

EID: 79851492750     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03939.x     Document Type: Article

References (26)

1. Shahani, S., Braga-Basaria, M., &, Basaria, S., (2008) Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. The Journal of Clinical Endocrinology and Metabolism, 93, 2042-2049. (Pubitemid 351831513)
2. Grossmann, M., Hamilton, E.J., Gilfillan, C., et al. (2010) Bone and Metabolic Health in Patients with Prostate Cancer Receiving Androgen Deprivation Therapy- Management Guidelines on behalf of the Endocrine Society of Australia, the Australian and New Zealand Bone and Mineral Society, and the Urological Society of Australia and New Zealand. Medical Journal of Australia, in press.
3. Hamilton, E.J., Ghasem-Zadeh, A., Gianatti, E., et al. (2010) Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. The Journal of Clinical Endocrinology and Metabolism, 95, E456-463.
4. Smith, M.R., (2007) Androgen deprivation therapy for prostate cancer: new concepts and concerns. Current Opinion in Endocrinology, Diabetes and Obesity, 14, 247-254. (Pubitemid 46684481)
5. Grossmann, M., Thomas, M.C., Panagiotopoulos, S., et al. (2008) Low testosterone levels are common and associated with insulin resistance in men with diabetes. The Journal of Clinical Endocrinology and Metabolism, 93, 1834-1840. (Pubitemid 351656526)
6. Grossmann, M., Gianatti, E.J., &, Zajac, J.D., (2010) Testosterone and type 2 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 17, 247-256.
7. Taylor, L.G., Canfield, S.E., &, Du, X.L., (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer, 115, 2388-2399.
8. Keating, N.L., O'Malley, A.J., Freedland, S.J., et al. (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. Journal of the National Cancer Institute, 102, 39-46.
9. Levine, G.N., D'Amico, A.V., Berger, P., et al. (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation, 121, 833-840.
10. Ketchandji, M., Kuo, Y.F., Shahinian, V.B., et al. (2009) Cause of death in older men after the diagnosis of prostate cancer. Journal of the American Geriatrics Society, 57, 24-30.
11. Greenspan, S.L., Coates, P., Sereika, S.M., et al. (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. The Journal of Clinical Endocrinology and Metabolism, 90, 6410-6417. (Pubitemid 41759293)
12. Morote, J., Morin, J.P., Orsola, A., et al. (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology, 69, 500-504. (Pubitemid 46428384)
13. Shahinian, V.B., Kuo, Y.F., Freeman, J.L., et al. (2005) Risk of fracture after androgen deprivation for prostate cancer. The New England Journal of Medicine, 352, 154-164. (Pubitemid 40096612)
14. Saylor, P.J., Kaufman, D.S., Michaelson, M.D., et al. (2010) Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. The Journal of Urology, 183, 2200-2205.
15. Ebeling, P.R., (2008) Clinical practice. Osteoporosis in men. The New England Journal of Medicine, 358, 1474-1482.
16. Smith, M.R., Egerdie, B., Hernandez Toriz, N., et al. (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. The New England Journal of Medicine, 361, 745-755.
17. Smith, M.R., Morton, R.A., Barnette, K.G., et al. (2010) Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. The Journal of Urology, 184, 1316-1321.
18. Basaria, S., Lieb II, J., Tang, A.M., et al. (2002) Long-term effects of androgen deprivation therapy in prostate cancer patients. Clinical Endocrinology (Oxford), 56, 779-786. (Pubitemid 34785910)
19. Galvao, D.A., Taaffe, D.R., Spry, N., et al. (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. Journal of Clinical Oncology, 28, 340-347.
20. Smith, D.P., King, M.T., Egger, S., et al. (2009) Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. British Medical Journal, 339, b4817.
21. Shahinian, V.B., Kuo, Y.F., Freeman, J.L., et al. (2006) Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Archives of Internal Medicine, 166, 465-471.
22. Handelsman, D.J., &, Zajac, J.D., (2004) 11: Androgen deficiency and replacement therapy in men. Medical Journal of Australia, 180, 529-535. (Pubitemid 38684625)
23. Irani, J., Salomon, L., Oba, R., et al. (2010) Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncology, 11, 147-154.
24. Potosky, A.L., Knopf, K., Clegg, L.X., et al. (2001) Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. Journal of Clinical Oncology, 19, 3750-3757. (Pubitemid 32844788)
25. Teloken, P.E., Ohebshalom, M., Mohideen, N., et al. (2007) Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer. The Journal of Urology, 178, 2521-2525. (Pubitemid 350052155)
26. Sharifi, N., Gulley, J.L., &, Dahut, W.L., (2005) Androgen deprivation therapy for prostate cancer. Journal of the American Medical Association, 294, 238-244. (Pubitemid 41043794)